opioid-epidemic
(2)
Sebby Borriello
Sebby Borriello is a pharmaceutical and medical-device commercialization veteran with 30-plus years of go-to-market leadership. After 25 years at Johnson & Johnson across wound management, biosurgery and aesthetics, he helped turn South Korea's SK Life Science from an R&D-only shop into a fully integrated US pharma company, leading the 2020 launch of its first FDA-approved drug, the epilepsy treatment XCOPRI. He later advised and joined Carmell Therapeutics as Chief Business Officer, and today serves as Executive Vice President and Chief Commercial Officer at MIDAS Healthcare Solutions, a New York startup tackling medication diversion and drug-waste accountability through its MidasVIEW platform and Anytime Witness video-verification technology.
MIDAS Healthcare Solutions, Inc.
MIDAS Healthcare Solutions builds technology that makes the disposal of leftover controlled substances in hospitals visible, verifiable and traceable. Its flagship system, MIDAS VIEW, combines a secure workstation, 360-degree video capture, AI-driven verification and chemical neutralization to close one of the quietest gaps in the fight against drug diversion and the opioid epidemic. Founded in 2017 by pharmacist Michael LaFauci, the New York-based company turns an untraceable, honor-system process into a documented, auditable record.